Message From The Director
Diabetes and obesity have reached epidemic proportions in the US and around the world. Founded in 2008, the Mount Sinai Diabetes Obesity Metabolism Institute (DOMI), the research counterpart to Mount Sinai’s nationally ranked Diabetes Center, was created in response to the rise of obesity, diabetes, and metabolic syndrome. It endeavors at the forefront of research to cure these disorders by developing better therapeutic and prevention strategies through basic and clinical research. The DOMI at Mount Sinai is a world leader in diabetes and obesity research, with broad focuses on many sub-disciplines within this space, ranging from very basic science through translational research, to community-based education and prevention programs. Mount Sinai recently has reinforced its commitment to this critical area through the recruitment of Dr. Andrew F. Stewart as its DOMI Scientific Director.
Areas of notable strength within the DOMI include excellence in: pancreatic beta cell research with an emphasis on human pancreatic beta cell regeneration and survival for the treatment of Types 1 and 2 diabetes; Type 1 diabetes autoimmunity; CNS control of appetite, feeding behavior and metabolic regulation of muscle, liver and adipocytes; mechanisms of insulin resistance and abnormal hepatic lipid metabolism; insulin, leptin, and growth factor-mediated intracellular signaling in liver, CNS, muscle and beta cells; the glycolytic switch in glycolysis and in cancer growth and metastasis; mechanisms of enhanced breast cancer risk and aggressiveness in women with diabetes; clinical trials in diabetes; bariatric surgery; body composition and metabolic abnormalities in Cushing’s Syndrome; genome-wide association studies in diabetes and obesity; genomics, bioinformatics of diabetes and obesity; direct patient care of people with diabetes, obesity, metabolic syndrome; vascular and renal complications of diabetes; research- and clinic-based personalized medicine in diabetes and obesity; bariatric surgery; direct patient care of patients with diabetes, obesity and metabolic syndrome; and, community outreach and education programs for prevention and management of diabetes.
At Mount Sinai, the DOMI has outstanding, state-of-the-art research facilities for high-throughput drug screens, high-content imaging, human and rodent bioinformatics and genomics, facilities for complete state-of-the-art rodent metabolic phenotyping, flow cytometry and cell sorting, in vivo animal and human imaging, microsurgery cores, advanced microscopy of all types, monoclonal antibody production facilities and real-time, electronic medical record-based bi-directional personalized medicine.
In addition to the excellent Endocrinology Division at Mount Sinai, the DOMI also has strong, collaborative and complimentary relationships with the Diabetes Centers at Columbia University College of Physicians and Surgeons, and Albert Einstein College of Medicine.
This extensive network supports the translational efforts at Mount Sinai to improve current care of Types 1 and 2 diabetes, obesity and metabolic syndrome, as well as to discover novel approaches and therapies to the management and ultimate cure of diabetes.
Although many and major strengths exist at Mount Sinai in the landscape of diabetes, we plan to expand further, and welcome inquiries from senior and junior scientists in the general areas, including, but not limited to, basic and clinical research in diabetes, obesity, autoimmunity, artificial pancreas, genomics and bioinformatics, adipocyte biology, inflammation and diabetes, vascular biology stem cell biology, microbiome and metabolism, and other areas.
Andrew Stewart, MD
Director, Diabetes, Obesity and Metabolism Institute
Diabetes, Obesity and Metabolism Institute
Mount Sinai Health System
One Gustave L. Levy Place
New York, NY 10029